- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06352346
A Single-case Design to Investigate a Compensatory Brain Game Supporting Goal Management Training Intervention in a Psychiatric Brain Injury Population
April 5, 2024 updated by: Helen Alexandra Anema, ProPersona
Evaluation of a Compensatory Brain Game Supporting Goal Management Training Intervention Targeting Executive Function in Acquired Brain Injury Patients With Depressive and/or Anxiety Symptoms: a Single-case Experimental Design
The main cognitive complaint in brain-injured patients is often the everyday disorganization caused by Executive Function (EF) deficits.
EF deficits are often seen in patients with psychiatric disorders i.e. depression or anxiety.
In order to minimize everyday disorganization, effective EF interventions are required.
Interventions using compensatory strategies have the potential to enable patients to minimize disabilities, minimize participation problems and to function more independently in daily life.
A well-known evidence-based intervention that uses compensatory strategies is Goal Management Training (GMT), a training that has been found to alleviate depressive symptoms in a depressed population.
GMT entails learning and applying an algorithm, in which a daily task is subdivided into multiple steps to handle executive difficulties of planning, and problem solving.
To adopt the GMT strategy and ensure maximal profitability for patients, they have to learn to use the algorithm in different situations and tasks.
Therefore, GMT is comprehensive, time-consuming and thus labour-intensive.
Along with this, brain games become increasingly attractive as an (add-on) intervention, most notably in an effort to develop home-based personalized care.
Until now, however, the rationale behind brain games is based on what can be considered the restorative approach (i.e.
strengthening of executive problems) rather than practicing compensatory strategies, with little or no transfer to improvements in daily life functioning.
This study therefore aims to assess the potential of a newly developed Brain Game, based on compensatory strategies, as an add-on to GMT to develop a shortened and partly self-paced GMT intervention.
The primary objective of this study is to assess whether the use of a compensatory brain game supported GMT treatment could be of interest in people with EF deficits after ABI that also suffer from depression or anxiety, to improve goal achievement, their executive function performance during goal-related tasks, and their executive performance during an ecological valid shopping task.
Also we assess whether psychological symptoms alleviate following the GMT intervention and at 6-weeks follow-up.
The study will be a multiple-baseline across individuals single-case experimental design (SCED).
The study population consists of brain-injured patients, between 18 and 75 years old that receive in-patient mental neuropsychiatric healthcare.
Participants eligible for the study must have EF deficits due to (nonprogressive) Acquired Brain Injury (ABI), minumum time post-onset of 3 months and depressive or anxiety symptoms.
EF deficits will be assessed by extensive neuropsychological examination.
Participants will be recruited from an inpatient clinic.
In the course of one and a half year four participants will be recruited.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Not provided
Study Type
Interventional
Enrollment (Estimated)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Helen Anema, PhD
- Phone Number: +31264833 313
- Email: h.anema@propersona.nl
Study Locations
-
-
Gelderland
-
Wolfheze, Gelderland, Netherlands, 6874 BE Wolfheze
- ProPersona
-
Contact:
- Bea Tiemens, PhD
- Email: b.tiemens@propersona.nl
-
Sub-Investigator:
- Floor Poerschke, MSc
-
Sub-Investigator:
- Emily Vink, MSc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age: 18 - 75 years
- Non-progressive acquired brain injury
- Minimal time post-onset of 3 months
- Receive inpatient neuropsychiatric care at the time of inclusion
- Executive deficits (neuropsychological assessment)
- Reasonable amount of awareness in their deficits, at least to the extent that they are motivated and capable to learn new skills with respect to their executive performance.
Exclusion Criteria:
- Inability to speak/understand the Dutch language
- Severe psychiatric disorders such as psychosis, manic episode, severe disruptive behavior
- Neurodegenerative disorders (i.e. dementia, Huntington, Parkinson
- Substance abuse (active)
- Severe cognitive comorbidity (i.e. Korsakov)
- Aphasia
- Neglect
- Unable to look at a computer screen for 15 minutes
- Unable to operate a keyboard or computer mouse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No Intervention: Baseline phase (Phase A)
o At the start of the study, all participants are assigned to the baseline phase (phase A).
During phase A, patients do not receive interventions related to executive function problems.
The start of the intervention phase (phase B) is determined randomly for each participant, given the restriction that phase A should last for at least three weeks (21 days) and at most five weeks (30 days).
This means that phase B can start on any day between the 21th and the 30th days, resulting in a total of 10 possible assignments.
So, in the first three weeks, all participants are in phase A. The duration of phase A will thus be different for each subject.
Phase A acts as a control and is therefore compared with phase B.
|
|
Experimental: Experimental: Intervention phase (Phase B): Goal Management Training
During the intervention phase (phase B), all included participants will have 6 sessions of Goal Management Training (GMT; twice per week) in which two individual chosen IADL-tasks will be subdivided into multiple steps under guidance of a therapist using the GMT method.
In addition participants play the compensatory brain game in which they are challenged to apply the learned GMT strategy in an imaginary and safe environment.
|
o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions.
In the treatment sessions, patients learn and apply the GMT algorithm.
This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist.
In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game.
Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session.
Besides, the intervention also includes a Plan Tool.
This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently.
The GMT treatment sessions are given twice a week (max.
60 minutes for each attendance).
|
No Intervention: Follow-up period
A follow-up period of six weeks takes place after phase B. During this follow-up period, patients receive no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in performance on the Oxford Multiple Errands Test- Dutch version (OxMET-NL) from phase A to phase B
Time Frame: The target behavior (i.e. performance on the OxMET-NL) will be measured repeatedly, two times a week, for the duration of phase A (3 to 5 weeks) and phase B (36 weeks
|
The target behavior will be assessed repeatedly, on a minimum of six occasions in phase A and B, in accordance with the recommendations of the What Works Clearinghouse and RoBiNT criteria (Tate et al., 2013).
The OxMET-NL task is a computer-tablet based version of the Multiple Errands Test and is scored automatically.
The task requires patients to buy six items and to answer two questions.
The main outcome measure of the task is accuracy which ranges from -10 to + 10 (higher score is better outcome) based on a score obtained in each shop.
|
The target behavior (i.e. performance on the OxMET-NL) will be measured repeatedly, two times a week, for the duration of phase A (3 to 5 weeks) and phase B (36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change on the Visual Analogue Scale (VAS) from phase A to phase B to follow-up
Time Frame: The VAS will be assessed repeatedly, two times a week, for the duration of phase A (3 to 5 weeks), phase B (3 weeks) and follow-up (6 weeks)
|
Subjective experience of strategy use in daily life and during the performance of instrumental activities of daily living (IADL) and three psychological symptoms.
Scale ranges from 0-100 of which higher scores means better outcome.
|
The VAS will be assessed repeatedly, two times a week, for the duration of phase A (3 to 5 weeks), phase B (3 weeks) and follow-up (6 weeks)
|
Change in performance on treatment goals as measured with the Goal Attainment Scale (GAS)
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
GAS is a mathematical technique for quantifying the achievement of goals set, used in rehabilitation.
GAS is described as a method of scoring the extent to which patient's individual goals are achieved in the course of intervention.
In effect, each patient has his or her own outcome measure, but this is scored in a standardized way as to allow statistical analysis.
The achievement of each goal (IADL-task) can be measured on a 5-point scale ranging from -2 to +2.
Outcomes can be quantified in a single aggregated goal attainment score.
This method gives a numerical T-score which is normally distributed about a mean of 50 (if the goals are achieved precisely) with a standard deviation of around this mean of 10 (if the goals are overachieved or underachieved).
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Change in performance on two trained IADL task (treatment goals)
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
Performance on two treatment goals is measured with a standardised scale .
The tasks will be divided into multiple steps using the GMT method.
Each task step will be assessed following a 3-point scale (ranging from 2=competent to 0=deficit).
Total scores per task will be adjusted to a 100-point scale using the following formula: performance = (total score / (number of steps × 2)) × 100.
Thus, a performance of 100% indicating perfect IADL task performance.
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Change in everyday difficulties in activities/participation as measured on the Daily Living Questionnaire (DLQ-R-NL)
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
The Dutch version of the Daily Living Questionnaire measures how much mental or cognitive difficulty the participant generally has by performing daily activities.
Scale ranges from 0-112 of which higher scores means better outcome.
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Change in strategy use during the performance of trained and untrained IADL tasks
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
A self-designed questionnaire to examine self-reported strategy use will also be administered after the performance of the trained and untrained IADL tasks in order to measure strategy use in a traditional memory task.
First, participants are openly asked which strategies they use during the performance of an IADL task.
Subsequently, they are given a list with possible strategy components of GMT that one could use to perform a task and are asked to place a check mark next to each strategy that they had used.
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Change in subjective experience of strategy use in daily life
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
GMT strategy use is assessed through an adjustment of the Strategy Use Inventory; SUI .
Participants have to indicate how often they use a certain strategy in daily life situations using a 5-point rating scale ranging from 1 (never) to 5 (often) which implies that higher scores mean better outcome.
Average item scores are calculated
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Change in subjectively experienced psychological symptoms such as depressive, anxiety and stress symptoms.
Time Frame: pre-intervention, immediately following intervention and at six weeks follow-up
|
Psychological symptoms are measured with the DASS-42.
The DASS is a 42-item self-report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress on a 4-point rating scale Subscale scores are calculated by summarizing the item scores, ranging from 0-42.
A higher score means worse outcome.
|
pre-intervention, immediately following intervention and at six weeks follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u.
- Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, McDonald S. Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: the 15-item Risk of Bias in N-of-1 Trials (RoBiNT) Scale. Neuropsychol Rehabil. 2013;23(5):619-38. doi: 10.1080/09602011.2013.824383. Epub 2013 Sep 9.
- Bertens D, Kessels RP, Boelen DH, Fasotti L. Transfer effects of errorless Goal Management Training on cognitive function and quality of life in brain-injured persons. NeuroRehabilitation. 2016;38(1):79-84. doi: 10.3233/NRE-151298.
- Dechamps A, Fasotti L, Jungheim J, Leone E, Dood E, Allioux A, Robert PH, Gervais X, Maubourguet N, Olde Rikkert MG, Kessels RP. Effects of different learning methods for instrumental activities of daily living in patients with Alzheimer's dementia: a pilot study. Am J Alzheimers Dis Other Demen. 2011 Jun;26(4):273-81. doi: 10.1177/1533317511404394. Epub 2011 Apr 17.
- Frankenmolen NL, Overdorp EJ, Fasotti L, Claassen JAHR, Kessels RPC, Oosterman JM. Memory Strategy Training in Older Adults with Subjective Memory Complaints: A Randomized Controlled Trial. J Int Neuropsychol Soc. 2018 Nov;24(10):1110-1120. doi: 10.1017/S1355617718000619. Epub 2018 Aug 31.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
March 29, 2024
First Submitted That Met QC Criteria
April 5, 2024
First Posted (Actual)
April 8, 2024
Study Record Updates
Last Update Posted (Actual)
April 8, 2024
Last Update Submitted That Met QC Criteria
April 5, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Plan Game_ABI&Psychiatry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Compensatory brain game supporting Goal Management Training intervention
-
Klimmendaal RevalidatiespecialistenRecruitingA Single-case Design to Investigate a Compensatory Strategy Game Supporting Goal Management TrainingAcquired Brain Injury | Executive Dysfunction | Goal Management Training | Compensatory Strategy Training | Serious GamingNetherlands
-
Klimmendaal RevalidatiespecialistenCompletedAcquired Brain Injury | Executive Dysfunction | Neuropsychological RehabilitationNetherlands
-
Sunnaas Rehabilitation HospitalUniversity of Oslo; Oslo University Hospital; University of GlasgowCompleted
-
Norwegian University of Science and TechnologyOslo University Hospital; St. Olavs Hospital; Norwegian Cancer SocietyActive, not recruitingChildhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia | Childhood Non-Hodgkin LymphomaNorway
-
BaycrestCentre for Aging and Brain Health InnovationCompletedAging | Cognitive DeclineCanada
-
VA Office of Research and DevelopmentCompletedMild Traumatic Brain InjuryUnited States
-
BaycrestUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; McGill... and other collaboratorsCompleted
-
St. Olavs HospitalOslo University HospitalCompleted
-
VA Office of Research and DevelopmentRecruitingPTSD | Brain Injury | Cognition | InterventionUnited States
-
Morehouse School of MedicineEmory UniversityUnknownSelf-management | Cardiovascular HealthUnited States